Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,718,775 papers from all fields of science
Search
Sign In
Create Free Account
Acomplia
Known as:
Zimulti
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
rimonabant
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Fighting falsified medicines: The analytical approach
H. Rebiere
,
P. Guinot
,
Denis Chauvey
,
C. Brenier
Journal of pharmaceutical and biomedical analysis
2017
Corpus ID: 6077567
Review
2014
Review
2014
Endocannabinoids, Related Compounds and Their Metabolic Routes
F. Fezza
,
M. Bari
,
R. Florio
,
E. Talamonti
,
M. Feole
,
M. Maccarrone
Molecules
2014
Corpus ID: 15945605
Endocannabinoids are lipid mediators able to bind to and activate cannabinoid receptors, the primary molecular targets…
Expand
Highly Cited
2009
Highly Cited
2009
Single application of a CB1 receptor antagonist rapidly following head injury prevents long-term hyperexcitability in a rat model
Julio C. Echegoyen
,
Caren Armstrong
,
R. Morgan
,
I. Soltesz
Epilepsy Research
2009
Corpus ID: 29937317
Review
2009
Review
2009
Endocannabinoids, sperm biology and human fertility.
S. Lewis
,
M. Maccarrone
Pharmacological research
2009
Corpus ID: 32577308
Review
2008
Review
2008
Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties
J. Bergman
,
M. Delatte
,
C. Paronis
,
K. Vemuri
,
G. Thakur
,
A. Makriyannis
Physiology & Behavior
2008
Corpus ID: 35280868
2008
2008
Rational design, synthesis and biological evaluation of new 1,5-diarylpyrazole derivatives as CB1 receptor antagonists, structurally related to rimonabant.
G. Menozzi
,
P. Fossa
,
E. Cichero
,
A. Spallarossa
,
A. Ranise
,
L. Mosti
European journal of medicinal chemistry
2008
Corpus ID: 38019234
Highly Cited
2007
Highly Cited
2007
PSNCBAM‐1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats
J. Horswill
,
U. Bali
,
+5 authors
P. Wong Kai In
British journal of pharmacology
2007
Corpus ID: 20321541
Rimonabant (AcompliaTM, SR141716A), a cannabinoid CB1 receptor inverse agonist, has recently been approved for the treatment of…
Expand
Review
2007
Review
2007
Rimonabant: Just an Antiobesity Drug? Current Evidence on Its Pleiotropic Effects
M. Bifulco
,
C. Grimaldi
,
P. Gazzerro
,
S. Pisanti
,
A. Santoro
Molecular Pharmacology
2007
Corpus ID: 3132054
The advent of the highly selective cannabinoid receptor (CB1) antagonist, rimonabant (SR141716; Acomplia) can revolutionize the…
Expand
2006
2006
Synthesis and structure-activity relationships (SARs) of 1,5-diarylpyrazole cannabinoid type-1 (CB(1)) receptor ligands for potential use in molecular imaging.
Sean R. Donohue
,
C. Halldin
,
V. Pike
Bioorganic & medicinal chemistry
2006
Corpus ID: 7051817
Highly Cited
2005
Highly Cited
2005
The role of CB1 receptors in sweet versus fat reinforcement: effect of CB1 receptor deletion, CB1 receptor antagonism (SR141716A) and CB1 receptor agonism (CP-55940)
S. Ward
,
L. Dykstra
Behavioural pharmacology
2005
Corpus ID: 24916618
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE